About
Science
Investors
Contact us
About
About BerGenBio
Management Team
Board of Directors
Scientific Advisory Board
Partners
Science
Pipeline
BEMCENTINIB | NSCLC
BEMCENTINIB | SRI
BEMCENTINIB | AML
Publications
Investors
Share Information and Policies
Share Data
Largest Shareholders
Stock Exchange Notices
Analyst Coverage
News
Financial Reports
Presentations
Financial Calendar
Corporate Governance
General Meetings
Environmental social and governance - ESG
Investor Relations
Contact us
Developing breakthrough AXL therapeutics to improve patients' lives
D
e
v
e
l
o
p
i
n
g
b
r
e
a
k
t
h
r
o
u
g
h
A
X
L
t
h
e
r
a
p
e
u
t
i
c
s
t
o
i
m
p
r
o
v
e
p
a
t
i
e
n
t
s
'
l
i
v
e
s
26 JUNE 2025, 10.00 AM CEST, AGM
Learn About Us
Read more
Latest news
Read more
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
Recent News
3rd June 2025
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
Read more
3rd June 2025
BerGenBio ASA: Notice of Annual General Meeting
Read more
29th April 2025
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar
Read more
26th March 2025
BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients
Read more
17th March 2025
BerGenBio announces advancement of its strategic review
Read more
26th February 2025
BerGenBio Fourth Quarter Results 2024
Read more
25th February 2025
BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives
Read more
18th February 2025
BerGenBio ASA: Invitation to fourth quarter 2024 results webcast
Read more
7th January 2025
BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial
Read more
All news
